This past fall, the National Institutes of Health, the Food and Drug Administration and other partners launched the Bespoke Gene Therapy Consortium in an effort to leverage adeno-associated viruses as vectors to treat rare diseases. The initiative seeks to streamline research to clinical use, driving efficiencies into the traditional research and development process. FDA leader Peter Marks and NIH’s P.J. Brooks discuss the consortium’s work and how it aims to help people with rare diseases.
HealthCast
Season 2
Episode 39
21m listen
Gene Therapy is Fighting Rare Diseases in FDA, NIH Program
Share
The technique aims to treat some diseases by gene replacement.
-
Dr. Peter Marks Director CBER, FDA -
Deputy Director, Office of Rare Diseases Research NCATS, NIH
Related Content
-
Inside Federal Acquisition and the Future of Cloud Buying
GSA’s Jonathan Plante discusses how federal cloud acquisition is shifting toward consolidation, transparency, cybersecurity and modernization.
9m watch -
A Former CDC AI Chief’s Advice for Navigating Careers Beyond Government
Travis Hoppe discusses AI in government, career growth and bringing public-sector values into industry.
4m watch -
AI Prototype Aims to Close Feedback Gaps Driving Marine Corps Attrition
PULSE Check gives commanders near-real-time insight into unit stressors, helping leaders address retention issues before Marines leave.
19m watch -
Meeting the War Department’s Edge Computing Challenge
Matt Barry discusses how HP Federal is supporting mission-critical environments with secure, resilient and interoperable edge technologies.
7m watch